Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Total Current Liabilities: 2017-2024

Historic Total Current Liabilities for Cidara Therapeutics (CDTX) over the last 8 years, with Dec 2024 value amounting to $49.6 million.

  • Cidara Therapeutics' Total Current Liabilities rose 116.15% to $95.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $95.8 million, marking a year-over-year increase of 116.15%. This contributed to the annual value of $49.6 million for FY2024, which is 26.50% down from last year.
  • Latest data reveals that Cidara Therapeutics reported Total Current Liabilities of $49.6 million as of FY2024, which was down 26.50% from $67.4 million recorded in FY2023.
  • Over the past 5 years, Cidara Therapeutics' Total Current Liabilities peaked at $67.4 million during FY2023, and registered a low of $34.0 million during FY2021.
  • Over the past 3 years, Cidara Therapeutics' median Total Current Liabilities value was $49.6 million (recorded in 2024), while the average stood at $52.8 million.
  • In the last 5 years, Cidara Therapeutics' Total Current Liabilities surged by 62.85% in 2023 and then dropped by 26.50% in 2024.
  • Cidara Therapeutics' Total Current Liabilities (Yearly) stood at $38.6 million in 2020, then decreased by 11.79% to $34.0 million in 2021, then grew by 21.70% to $41.4 million in 2022, then skyrocketed by 62.85% to $67.4 million in 2023, then declined by 26.50% to $49.6 million in 2024.